Sugi Predict

Sugi Predict / Compounds / SCHEMBL3280264

SCHEMBL3280264

SCHEMBL3280264

CN(C)C(=O)C1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GFER P55789 4/20 0.51
▸ CASP6 P55212 1/20 0.51
▸ PDK2 Q15119 1/20 0.49
▸ SYK P43405 2/20 0.47
▸ RORC P51449 1/20 0.47
▸ NOTUM Q6P988 1/20 0.47
▸ MAPT P10636 4/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ GAA P10253 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ADRA2C P18825 1/20 0.46
▸ PTK2B Q14289 1/20 0.46
▸ ESR2 Q92731 1/20 0.46
▸ CYP46A1 Q9Y6A2 6/20 0.44
▸ EED O75530 1/20 0.43
▸ USP2 O75604 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3576843 0.98 GFER (0.50) GFERCASP6PDK2SYKRORC
SCHEMBL20887573 0.91 NOTUM (0.57) GFERCASP6PDK2SYKNOTUM
SCHEMBL12074079 0.86 CYP46A1 (0.50) PDK2SYKRORCNOTUMMAPT
SCHEMBL14924001 0.85 RORC (0.51) PDK2SYKRORCNOTUMMAPT
SCHEMBL14241715 0.84 CYP46A1 (0.50) PDK2SYKRORCNOTUMKDM4E
Hydrochloric Acid SCHEMBL3578892 0.84 GFER (0.46) GFERCASP6PDK2SYKRORC
SCHEMBL4889125 0.84 NOTUM (0.58) PDK2RORCNOTUMKMT2ACYP46A1
SCHEMBL14320629 0.82 ALDH1A1 (0.52) GFERCASP6SYKNOTUMMAPT
SCHEMBL21418385 0.82 GFER (0.60) GFERCASP6NOTUMMAPTKDM4E
SCHEMBL4476298 0.82 RORC (0.54) GFERPDK2SYKRORCNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070748-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2021-03-11 — — US disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20200079754-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2020-03-12 — — US disclosed
US-20190100505-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2019-04-04 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-20180305348-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC 2018-10-25 — — US disclosed
US-10052330-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2018-08-21 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
EP-3310776-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE Pharmacyclics LLC (US) 2018-04-25 — — EP disclosed
US-20180030027-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2018-02-01 — — US disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
WO-2012167733-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2012-12-13 — — WO disclosed
WO-2012143144-A1 PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 — — WO disclosed
WO-2012143143-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 — — WO disclosed
WO-2011162515-A2 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHD3ITION OF TYROSINE KINASE ACTIVITY HANMI HOLDINGS CO. , LTD. (KR) 2011-12-29 — — WO disclosed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 — — US disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — WO disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — WO disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070748-A1 INHIBITORS OF BRUTONS TYROSINE KINASE BTK, LYN, LCK GFER 3465/4885CASP6 1574/4885PDK2 1912/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK GFER 3828/4885CASP6 3379/4885PDK2 518/4885
US-20180030027-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LYN, LCK GFER 3357/4885CASP6 1498/4885PDK2 2369/4885
US-20200079754-A1 INHIBITORS OF BRUTONS TYROSINE KINASE BTK, LYN, LCK GFER 3465/4885CASP6 1574/4885PDK2 1912/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK GFER 3828/4885CASP6 3379/4885PDK2 518/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 GFER 3779/4885CASP6 3137/4885PDK2 465/4885
US-10052330-B2 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors SYK, BTK, TYRO3 GFER 2489/4885CASP6 1743/4885PDK2 1029/4885
US-20190100505-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LYN, LCK GFER 3435/4885CASP6 1587/4885PDK2 2392/4885
US-20090054425-A1 PROTEIN KINASE INHIBITORS SYK, JAK2, BTK GFER 2866/4885CASP6 2345/4885PDK2 1569/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GFER 3792/4885CASP6 3264/4885PDK2 536/4885
US-20180305348-A1 INHIBITORS OF BRUTONS TYROSINE KINASE BTK, LYN, LCK GFER 3465/4885CASP6 1574/4885PDK2 1912/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GFER 3792/4885CASP6 3264/4885PDK2 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.